<DOC>
	<DOCNO>NCT00802945</DOCNO>
	<brief_summary>This multicenter , open-label , two-arm , 2-stage , Phase 2 study NKTR-102 patient metastatic locally advanced breast cancer whose disease fail prior taxane-based treatment metastatic setting . Patients randomize 1:1 one two treatment arm . NKTR 102 administer dose level 145 mg/m2 arm . In Arm A , NKTR-102 give q14d schedule . In Arm B , NKTR-102 give q21d schedule . Approximately 70 patient may evaluate study approximately 35 patient enrol treatment arm .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy NKTR-102 Patients With Metastatic Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Inoperable metastatic locally advanced breast cancer 2 . No 2 prior chemotherapy regimen give metastatic locally advanced set prior treatment metastatic setting must include taxane 1 . Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior Day 1 Cycle 1 2 . Patients major surgery within 4 week prior Day 1 Cycle minor surgery within 2 week prior Day 1 Cycle 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>